2025-11-06 - Analysis Report
Okay, here's an analysis of Salesforce Inc. (CRM) based on the provided data, focusing on key performance indicators and recent news.

## Salesforce Inc. (CRM) Analysis

### 1. Performance vs. S&P 500 (VOO)

*   **Ticker:** CRM
*   **Company:** Salesforce Inc. (Provides cloud-based software for customer relationship management.)

**Key Numbers:**

*   **CRM Cumulative Return:** -6.42%
*   **VOO Cumulative Return:** 99.52%
*   **Absolute Divergence (Last Day):** -111.4
*   **Relative Divergence:** 0.0% (at the very bottom of its historical range relative to VOO)

**Analysis:**

CRM has significantly underperformed the S&P 500 (VOO). The -111.4% divergence indicates a large gap in returns. A Relative Divergence of 0.0% suggests that CRM's performance is at the low end of its historical range compared to VOO.

**Alpha, Beta Analysis**

| Year       | CAGR  | MDD   | Alpha | Beta  | Cap(B) |
| :----------- | :---- | :---- | :---- | :---- | :----- |
| 2015-2017  | 39.0% | 70.6% | 10.0% | -0.0  | 97.3   |
| 2016-2018  | 34.0% | 73.5% | 19.0% | 0.1   | 130.4  |
| 2017-2019  | 22.0% | 73.5% | 0.0%  | 0.4   | 154.8  |
| 2018-2020  | 14.0% | 73.5% | -10.0% | 0.4   | 211.9  |
| 2019-2021  | 37.0% | 71.9% | -10.0% | 0.7   | 242.0  |
| 2020-2022  | -78.0% | 74.7% | -78.0% | 0.4   | 126.2  |
| 2021-2023  | -47.0% | 76.6% | -49.0% | -0.6  | 250.5  |
| 2022-2024  | -42.0% | 76.6% | -63.0% | -0.4  | 318.3  |
| 2023-2025  | 5.0%  | 76.6% | -59.0% | -2.0  | 241.8  |

**Analysis**
* **CAGR Trends**: The CAGR (Compound Annual Growth Rate) has varied significantly over different periods, indicating fluctuating growth patterns. Notably, the CAGR was strong between 2015 and 2019, but it declined sharply in the subsequent years.
* **MDD (Maximum Drawdown)**: The high MDD values (around 70-77%) suggest that Salesforce has experienced substantial declines from peak to trough in the evaluated periods.
* **Alpha**: Salesforce's alpha values vary significantly, from positive values in the early periods (indicating outperformance relative to the benchmark) to sharply negative values in recent periods (indicating significant underperformance). The recent negative alphas (-78.0% to -59.0%) suggest that factors beyond market movements are impacting the stock negatively.
* **Beta**: The beta values fluctuate and have been negative recently (-0.6 to -2.0), implying that Salesforce has become less correlated with the market and potentially moving in the opposite direction.
* **Market Capitalization (Cap)**: The market capitalization shows periods of growth, particularly until 2024, but declines by 2025, reflecting changing investor sentiment and market conditions.

### 2. Recent Stock Price Action

*   **Current Price:** 253.91
*   **Last Market Data:** Price: 254.0, Previous Close: 254.44, Change: -0.17
*   **5-Day Moving Average:** 256.75
*   **20-Day Moving Average:** 250.64
*   **60-Day Moving Average:** 246.61

**Analysis:**

The current price is slightly below the 5-day moving average but above the 20-day and 60-day moving averages. This suggests a potential short-term pullback, but the longer-term trend might still be upward. The change of -0.17 from the previous close is not a significant move.

### 3. Technical Indicators & Outlook

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 63.67 (Approaching Overbought)
*   **PPO:** 0.24
*   **Hybrid Signal:**  cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Delta_Previous_Relative_Divergence (20-day):** -5.7 (Short-term decline)
*   **Expected Return (%):** -4728.7% (Long-term underperformance vs. S&P 500)

**Analysis:**

*   **MRI:**  Indicates a relatively safe investment environment, which is contradictory to the other factors.
*   **RSI:** An RSI of 63.67 suggests the stock is approaching overbought territory, implying a potential pullback in the near term.
*   **PPO:** The Positive Price Oscillator (PPO) is positive but relatively small, indicating slight bullish momentum.
*   **Delta_Previous_Relative_Divergence:**  The negative change in relative divergence indicates a short-term weakening of CRM compared to VOO.
*   **Expected Return:** The extremely negative expected return suggests significant concerns about long-term relative performance.

### 4. Recent News & Significant Events

*   **Positive:** Dan Ives (GuruFocus.com) is positive on Palantir (a competitor or partner?)
*   **Competition:** Salesforce faces competition from Sierra, which is hosting a developer conference focusing on AI agents.
*   **Partnerships & Expansions:** Blackthorn is expanding its event suite, and Verato's healthcare partnership could strengthen Salesforce's regulated market strategy.
*   **General:** Appfire received an award, and Alchemer Connect is powering workflows.

**Analysis:**

The news is a mixed bag.  The competitive pressure from Sierra and the underperformance vs. the S&P 500 are concerns. However, partnerships and expansions suggest the company is actively working to grow.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 1.65)
*   **Target Price:** Avg: 331.81 / High: 430.00 / Low: 221.00
*   **Recent Rating Changes:**  Not specified, implying no recent significant changes.

**Analysis:**

Analysts, on average, have a "Buy" rating on CRM, and the average target price is significantly higher than the current price.  This suggests they believe the stock is undervalued.  However, the low target price of 221 is below the current price, indicating disagreement among analysts.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue     |
| :--------- | :--- | :---------- |
| 2025-09-04 | 1.97 | 10.24 B$ |
| 2025-05-29 | 1.61 | 9.83 B$  |
| 2024-12-04 | 1.6  | 9.44 B$  |
| 2024-08-29 | 1.48 | 9.32 B$  |
| 2025-09-04 | 1.48 | 9.32 B$  |

**Analysis:**

EPS and revenue are generally trending upwards, suggesting positive business growth. The latest EPS is the highest in the series.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
| :--------- | :--------- | :-------------- |
| 2025-07-31 | $10.24B    | 78.10%          |
| 2025-04-30 | $9.83B     | 76.96%          |
| 2025-01-31 | $9.99B     | 77.81%          |
| 2024-10-31 | $9.44B     | 77.71%          |
| 2024-07-31 | $9.32B     | 76.85%          |

**Capital and Profitability:**

| Quarter    | Equity     | ROE   |
| :--------- | :--------- | :---- |
| 2025-07-31 | $61.33B    | 3.08% |
| 2025-04-30 | $60.67B    | 2.54% |
| 2025-01-31 | $61.17B    | 2.79% |
| 2024-10-31 | $58.52B    | 2.61% |
| 2024-07-31 | $57.63B    | 2.48% |

**Analysis:**

*   **Revenue:**  Revenue has generally increased over the past year.
*   **Profit Margin:**  Profit margins are very high and consistent, indicating strong operational efficiency.
*   **Equity:**  Equity has also increased, indicating financial strength.
*   **ROE:**  Return on Equity (ROE) has fluctuated but is generally increasing, suggesting improving profitability relative to shareholder equity.

### 7. Overall Summary

*   **Underperformance:**  CRM has significantly underperformed the S&P 500.  The expected return is alarming.
*   **Technical Signals:**  Mixed signals. The RSI suggests it's approaching overbought. The Delta_Previous_Relative_Divergence shows short-term weakness.
*   **Financial Health:**  The company has strong revenue, profit margins, and equity, suggesting a healthy underlying business.
*   **Analyst Sentiment:**  Analysts are generally positive, but there's disagreement on the potential upside.
*   **News & Events:**  There's competitive pressure, but the company is also pursuing partnerships and expansions.

**Conclusion:**

CRM presents a mixed picture. While the financial metrics and analyst ratings suggest a potentially undervalued company, the underperformance compared to the S&P 500 and the negative expected return are significant concerns. The mixed technical signals and competitive landscape add to the uncertainty. Further investigation is warranted to determine if the underperformance is temporary or indicative of deeper issues. The high MRI might be misleading given the other negative factors.
